Related references
Note: Only part of the references are listed.EFFICACY OF CANAKINUMAB, ON A REDUCED DOSE OR A PROLONGED DOSE INTERVAL WITHOUT CONCOMITANT CORTICOSTEROIDS AND METHOTREXATE, IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
Pierre Quartier et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Time spent in inactive disease before MTX withdrawal is relevant with regard to the flare risk in patients with JIA
Jens Klotsche et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Flares After Withdrawal of Biologic Therapies in Juvenile Idiopathic Arthritis: Clinical and Laboratory Correlates of Remission Duration
Gabriele Simonini et al.
ARTHRITIS CARE & RESEARCH (2018)
Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials
Nicolino Ruperto et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans
Yukiko Kimura et al.
PEDIATRIC RHEUMATOLOGY (2017)
How common is remission in juvenile idiopathic arthritis: A systematic review
Stephanie J. W. Shoop-Worrall et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2017)
Update on the management of systemic juvenile idiopathic arthritis and role of IL-1 and IL-6 inhibition
Sriharsha Grevich et al.
ADOLESCENT HEALTH MEDICINE AND THERAPEUTICS (2017)
The risk and nature of flares in juvenile idiopathic arthritis: results from the ReACCh-Out cohort
Jaime Guzman et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Tapering and withdrawal of tocilizumab in patients with systemic juvenile idiopathic arthritis in inactive disease: results from an alternative dosing regimen in the TENDER study
F De Benedetti et al.
Pediatric Rheumatology (2014)
Effectiveness of First-Line Treatment With Recombinant Interleukin-1 Receptor Antagonist in Steroid-Naive Patients With New-Onset Systemic Juvenile Idiopathic Arthritis Results of a Prospective Cohort Study
Sebastiaan J. Vastert et al.
ARTHRITIS & RHEUMATOLOGY (2014)
The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis
Dirk Holzinger et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
American College of Rheumatology Provisional Criteria for Defining Clinical Inactive Disease in Select Categories of Juvenile Idiopathic Arthritis
Carol A. Wallace et al.
ARTHRITIS CARE & RESEARCH (2011)
Methotrexate Withdrawal at 6 vs 12 Months in Juvenile Idiopathic Arthritis in Remission A Randomized Clinical Trial
Dirk Foell et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support
Paul A. Harris et al.
JOURNAL OF BIOMEDICAL INFORMATICS (2009)
Share Paper
